The effect of tocilizumab on clinical signs and laboratory findings in rheumatoid arthritis patients resistant to methotrexate

AbstractRheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease that mainly affects joint damage followed by increased morbidity and mortality rates. The progressive increase of inflammation factors, especially IL-6, is seen during the course of this condition. The aim of this study was to evaluate the effect of tocilizumab (TCZ) in patients with severe to moderate resistant RA with an inadequate response to treatment with disease-modifying antirheumatic drugs (DMARDs). We also reviewed the safety of the drug and related complications. Twelve selected RA patients received 8  mg/kg of TCZ every 4 weeks for over 24 weeks; we evaluated inflammatory factor like ESR, lipid profile, comprehensive physical exam, and RA activity like Disease Activity Score (DAS) 28, Short Form (36) Health Survey (SF-36), and ACR50 to calculate the swollen and tender joint counts. DMARDs wer e simultaneously administered. First-level response and secondary response were defined as reaching the American College of Rheumatology 20% response criteria (ACR20) within 24 weeks of treatment and Disease Activity Score (DAS) 28, Short Form (36) Health Survey (SF-36), and ACR50, respectively. Al l patients achieved ACR20 after 24 weeks and 83% reached ACR50 (p 
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research

Related Links:

Autoimmune rheumatic diseases, such as Sjögren syndrome (SS) and rheumatoid arthritis (RA), are characterized by chronic inflammation and autoimmunity, which cause joint tissue damage and destruction by triggering reduced mobility and debilitation in patients with these diseases. Initiation and maintenance of chronic inflammatory stages account for several mechanisms that involve immune cells as key players and the interaction of the immune cells with other tissues. Indeed, the overlapping of certain clinical and serologic manifestations between SS and RA may indicate that numerous immunologic-related mechanisms are i...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Abstract Autoimmune diseases, such as rheumatoid arthritis, systematic lupus erythematosus and Sjögren's syndrome, are a group of diseases characterized by the activation of immune cells and excessive production of autoantibodies. Although the pathogenesis of these diseases is still not completely understood, studies have shown that multiple factors including genetics, environment and immune responses play important roles in the development and progression of the diseases. In China, there are great achievements in the mechanisms of autoimmune diseases during the last decades. These studies provide new insight...
Source: Advances in Immunology - Category: Allergy & Immunology Authors: Tags: Adv Immunol Source Type: research
Authors: Rajabinejad M, Salari F, Gorgin Karaji A, Rezaiemanesh A Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of the immature myeloid cells that are derived from the myeloid progenitors with immunosuppressive functions. MDSCs are accumulated in the inflammatory sites during some autoimmune disorders, such as rheumatoid arthritis (RA) and can be an important factor in the pathogenesis of these diseases. Some research has shown the anti-inflammatory role of MDSCs during the RA progression and supports the hypothesis that MDSCs can be a potential treatment option for autoimmunity with t...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Authors: El Jammal T, Gerfaud-Valentin M, Sève P, Jamilloux Y Abstract In the past ten years, the better understanding of the pathophysiological mechanisms underlying inflammatory and autoimmune diseases has led to the emergence of many targeted therapies. Among them, the Janus kinase inhibitors are acting upstream in the inflammatory cascade of several key cytokines in disorders such as rheumatoid arthritis, ulcerative colitis or psoriasis. At the moment, these three diseases represent the only indications validated by the FDA and the EMA of the use of JAK inhibitors apart from hematology. Preclinical data ...
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
CONCLUSIONS: According to the proposed algorithm, ANA IIF+MFI- subjects should be screened by an alternative solid-phase assay such as line-immunoassay or ELISA. PMID: 31694754 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
CONCLUSIONS: These results indicated that FER1L4 regulates RA via targeting NLRC5 potentially. Therefore, this study may provide a candidate therapeutic target for RA. PMID: 31694750 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
ObjectiveMucosa ‐associated lymphoid tissue lymphoma translocation protein 1 (MALT‐1) plays a crucial role in innate and adaptive immune signaling by modulating the threshold for activation of immune cells, including Treg cells. Therefore, MALT‐1 is regarded to be an interesting therapeutic target in several immune‐mediated diseases. The goal of this study was to examine the role of MALT‐1 in experimental animal models of rheumatoid arthritis (RA).MethodsMALT ‐1 activation was assessed by measuring cleavage of the deubiquitinase CYLD in lymphocytes from mice with collagen‐induced arthritis (CIA). Furthermore,...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
We report a case of minimal change disease (MCD) that developed in a woman receiving the TNF-α inhibitor certolizumab and was resolved with high-dose steroids and discontinuation of TNF-α blockade. PMID: 31676702 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
ConclusionsOur results show that TSCM, including expanded clones specific for relevant autoantigens, accumulate in RA patients not exposed to biologic agents, and might be involved in the natural history of the disease. Further analysis of TSCM dynamics in autoimmune disorders may have implications for the design and efficacy assessment of innovative therapies.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
AbstractThe idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases resulting from inflammation of muscle and manifesting as weakness, though a range of extra-muscular manifestations are observed. These are often correlated closely with disease subtype and the presence of myositis-specific/myositis-associated antibodies. IIM are notoriously difficult to treat and often refractory to glucocorticoid therapy and synthetic immunosuppressants. Both the innate and adaptive immune systems are implicated in the pathogenesis of IIM. A growing understanding of the key cytokines as well as the cell-mediated and an...
Source: Rheumatology International - Category: Rheumatology Source Type: research
More News: Actemra | Arthritis | Autoimmune Disease | Laboratory Medicine | Methotrexate | Pathology | Rheumatoid Arthritis | Rheumatology | Study